ASCO 2023 | Final analysis of distant metastasis-free survival in the KEYNOTE-716 study
Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, comments on the distant metastasis-free survival (DMFS) analysis from the Phase III KEYNOTE-716 trial (NCT03553836) of pembrolizumab in patients with stage 2B or 2C cutaneous melanoma. The primary end point was relapse-free survival (RFS) while the secondary endpoint was distant-metastases free survival (DMFS). This benefit of adjuvant pembrolizumab over placebo was demonstrated independent of cancer stage at baseline, and DMFS was additionally superior in patients receiving pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Read more...
Cookie settings
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.